Who Paid My Doc
Robert Rose
Family Medicine King William, VA Medical Doctor
NPI 1730527342 CMS profile 640609
1041 Sharon Rd Ste 205, Ste 205, King William, VA 23086
General payments
$22,000
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Robert Rose of King William, VA is reported in the CMS Open Payments database as having received $22,000 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $22,000 | 1 |
Beside peers
- Robert Rose
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Robert Rose were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Robert Rose | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $150 | $41–$543 | $163 |
| 2020 | $0 | $120 | $32–$415 | $114 |
| 2021 | $0 | $137 | $35–$551 | $132 |
| 2022 | $22,000 | $137 | $37–$512 | $149 |
| 2023 | $0 | $149 | $42–$545 | $160 |
| 2024 | $0 | $156 | $44–$560 | $164 |
| 2025 | $0 | $155 | $45–$549 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 156 drugsPart D claims
10,703
Drug cost
$689,328
Branded share of claims
15.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 70 | $95,183 | |
| Eliquis Apixaban | Brand | 77 | $82,421 | |
| Trulicity Dulaglutide | Brand | 41 | $80,097 | |
| Ozempic Semaglutide | Brand | 41 | $71,104 | |
| Xarelto Rivaroxaban | Brand | 23 | $36,017 | |
| Mounjaro Tirzepatide | Brand | 29 | $35,362 | |
| Risperdal Consta Risperidone Microspheres | Brand | 12 | $28,327 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 19 | $24,860 | |
| Januvia Sitagliptin Phosphate | Brand | 18 | $23,372 | |
| Farxiga Dapagliflozin Propanediol | Brand | 23 | $20,096 |
The 10 drugs with the highest cost, of 156 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$90,117
Medicare patients
473
Services billed
1,167
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 42% | |
| Diabetes | 35% | |
| Chronic kidney disease | 30% | |
| Ischemic heart disease | 22% | |
| Atrial fibrillation | 19% | |
| Cancer | 18% | |
| Depression | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Virginia
Related records
Family Medicine in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.